Recently, the Beijing Cosmetics Review and Inspection Center has published a series of Q&A regarding ordinary cosmetics filing. The following content is primarily excerpted from the 53rd issue, compiled by CIRS Group for reference.

Starting March 1, 2026, a total of 12 cosmetic testing methods will be officially implemented in China. CIRS Group has summarized them for reference.

In February 2026, the National Medical Products Administration, along with the Medical Products Administrations of Guangxi Zhuang Autonomous Region, Hunan Province, and Beijing, issued announcements regarding cosmetic supervision and sampling inspections. A total of 71 batches of products were found to be non-compliant. This summary of the announcements aims to help enterprises stay informed of evolving regulatory trends and strengthen their quality management and compliance awareness.

This article compiles and summarizes the latest developments in cosmetics regulations as of January 2026, including domestic China industry news, newly issued regulations, updates to relevant standards and policies, and regulatory requirements, as well as global regulatory trends in the cosmetics sector. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.

Based on data retrieved from China’s National Medical Products Administration (NMPA), seven new cosmetic ingredients have been filed between February 1 and 5, 2026. Detailed information is provided in the table below. At present, the associated technical specifications have not been made public, and the ingredient has not yet entered the post-filing monitoring period. As of now in 2026, a total of 26 new cosmetic ingredients have been filed.

On February 6, 2026, China’s National Institutes for Food and Drug Control (NIFDC) released six draft standards for the formulation and revision of microbiological examination methods in cosmetics. Public comments are now being solicited, with the deadline set for March 22, 2026.

To help stakeholders stay informed of the latest developments and gain insights into market trends, this article provides a systematic review and in-depth analysis of the cosmetic ingredient filings published by China’s National Medical Products Administration (NMPA) in January 2026. The report mainly covers the number of new ingredient filings during the month, basic information about the filing enterprises, the regional distribution of domestic filers, ingredients that have been filed multiple times, and interpretations of selected ingredients. It aims to offer valuable data support and information references for the cosmetics industry.

On January 29, 2026, the Information Center of the China National Medical Products Administration (NMPA) released an operational guide to facilitate the implementation of the Notice on Launching the Pilot Program for Electronic Labels of Cosmetics. The guide is intended to assist pilot enterprises in the standardized submission of electronic label information and related documentation, and to clarify the specific submission requirements.

In January 2026, China’s National Medical Products Administration (NMPA), along with the Shandong and Guangdong Provincial Medical Products Administrations, successively issued public notices on the regulatory sampling and testing of cosmetics. A total of 61 batches of products were found to be non-compliant with relevant regulations. In addition, the Jiangxi and Shandong Provincial Medical Products Administrations released inspection reports on cosmetic manufacturers, identifying 33 enterprises with regulatory issues.

Following FAQs are all related to ordinary cosmetics filing, CIRS Group has compiled the information and translated them into English for your reference.